Eupolio Polio Vaccine Description
Eupolio Polio Vaccine is a Sabin-Inactivated Polio Vaccine (Sabin-IPV). The main advantage of using attenuated Sabin poliovirus strains in IPV production is that there is a lower biosafety risk than wild-type polioviruses used to manufacture conventional IPVs, which has the potential to pose a biosafety hazard in case they escape from the manufacturing facility.
Eupolio is the first Sabin-IPV to obtain WHO prequalification in late December 2020. The main advantage of using attenuated Sabin poliovirus strains in IPV production is that there is a lower biosafety risk compared to wild-type polioviruses used to manufacture conventional IPVs, which has the potential to pose a biosafety hazard in case they escape from the manufacturing facility.
LG Chem initiated the development of Eupolio™ in 2014 and invested in the construction of state of the art WHO Global Action Plan III compliant manufacturing facility in Osong, Korea.
Eupolio™ demonstrated excellent phase III results in 2019, inducing high antibody titers against both wild-type and Sabin polioviruses, which will also protect against circulating vaccine-derived polioviruses (cVDPV) that make up the majority of polio cases in recent years.
LG Chem rapidly developed clinical products and processes through active facility investment since the beginning of the vaccine development. The Bill and Melinda Gates Foundation, the largest health-related support organization in the world, had provided a total of US$57.6 million in support funds for the Eupolio and Eupolio-based Mixed Vaccine Projects since 2017 by highly recognizing LG Chem's capabilities.
Since its establishment in 1947, LG Chem has continuously achieved growth through endless challenges and innovations as Korea’s leading chemical company.
Eupolio Polio Vaccine Indication
Eupolio is indicated to protect both wild-type and Sabin polioviruses, which will also protect against circulating vaccine-derived polioviruses (cVDPV) that make up most of the polio cases in recent years.
Eupolio Polio Vaccine News
January 8, 2021 - LG Chem announced that it had signed a contract with UNICEF to supply US$80 million worth of polio vaccine Eupolio from 2021 to 2022. The contract will make LG Chem one of the top three suppliers of polio vaccines to UNICEF as the company will account for more than 20 percent of UNICEF's procurement volume.
January 7, 2021 - LG Chem to Contribute to Global Polio Eradication with Eupolio™, the First Sabin Inactivated Polio Vaccine to Receive WHO Prequalification. WHO prequalification of Eupolio™ is a major milestone in ongoing efforts towards global polio eradication. It will help close the gap between demand and supply of safe and effective Inactivated Polio Vaccine (IPV) for millions of infants in need of immunization against poliovirus.
October 15, 2019 - WHO-UNICEF Consultation with OPV/IPV Manufacturers, National Authorities for Containment, and National Regulatory Authorities.
March 11, 2019 - LG Chem announced that it would receive support from the Bill & Melinda Gates Foundation to develop a hexavalent vaccine to prevent six diseases ― diphtheria, tetanus, whooping cough (pertussis), hepatitis B, Haemophilus influenzae type B, and polio.
Eupolio Polio Vaccine Clinical Trials
Clinical Trial NCT03169725: A Phase 2/3 Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants. Last Update Posted: August 29, 2019.